Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 18/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.89 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.84 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.76 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16361558 | 1.00 | ADORA3 (1.00) | ADORA3KCNH2ABCG2ADORA2AADORA1 | |
| SCHEMBL21779332 | 1.00 | ADORA3 (1.00) | ADORA3KCNH2ABCG2ADORA2AADORA1 | |
| SCHEMBL10322552 | 1.00 | ADORA3 (1.00) | ADORA3KCNH2ABCG2ADORA2AADORA1 | |
| SCHEMBL20122178 | 1.00 | ADORA3 (1.00) | ADORA3KCNH2ABCG2ADORA2AADORA1 | |
| SCHEMBL16774365 | 1.00 | ADORA3 (1.00) | ADORA3KCNH2ABCG2ADORA2AADORA1 | |
| SCHEMBL19464922 | 1.00 | ADORA3 (1.00) | ADORA3KCNH2ABCG2ADORA2AADORA1 | |
| SCHEMBL31061297 | 1.00 | ADORA3 (1.00) | ADORA3KCNH2ABCG2ADORA2AADORA1 | |
| SCHEMBL19459897 | 0.95 | ADORA3 (0.91) | ADORA3KCNH2ABCG2ADORA2AADORA1 | |
| SCHEMBL19799157 | 0.95 | ADORA3 (0.91) | ADORA3KCNH2ABCG2ADORA2AADORA1 | |
| SCHEMBL19464859 | 0.94 | ADORA3 (0.89) | ADORA3KCNH2ABCG2ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186486-A1 | POTENTIATION OF DURABLE ANTITUMOR IMMUNITY BY MULTIFACTORIAL IMMUNE MODULATION | BAYLOR COLLEGE OF MEDICINE (US) | 2025-06-12 | — | — | US | claimed |
| EP-4493166-A1 | POTENTIATION OF DURABLE ANTITUMOR IMMUNITY BY MULTIFACTORIAL IMMUNE MODULATION | Baylor College of Medicine (US) | 2025-01-22 | — | — | EP | claimed |
| CN-119278032-A | Enhancement of persistent antitumor immunity by multifactorial immunomodulation | 贝勒医学院 | 2025-01-07 | — | — | CN | claimed |
| WO-2023177870-A1 | POTENTIATION OF DURABLE ANTITUMOR IMMUNITY BY MULTIFACTORIAL IMMUNE MODULATION | BAYLOR COLLEGE OF MEDICINE (US) | 2023-09-21 | — | — | WO | claimed |
| US-20250345353-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS INC (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4611724-A1 | COMPOSITIONS FOR INTRAVENOUS ADMINISTRATION | Astrocyte Pharmaceuticals, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4611765-A2 | FAST-DISSOLVING DOSAGE FORMS AND USES THEREOF | Astrocyte Pharmaceuticals, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-12397010-B2 | Treatment of chronic headaches | SAINT LOUIS UNIVERSITY (US) | 2025-08-26 | — | — | US | disclosed |
| US-12390483-B2 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250186486-A1 | POTENTIATION OF DURABLE ANTITUMOR IMMUNITY BY MULTIFACTORIAL IMMUNE MODULATION | BAYLOR COLLEGE OF MEDICINE (US) | 2025-06-12 | — | — | US | disclosed |
| US-20250177405-A1 | METHODS OF TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS, INC. | 2025-06-05 | — | — | US | disclosed |
| US-12239654-B2 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| CN-110003212-B | A3 adenosine receptor agonists | 美国卫生和人力服务部 | 2022-12-06 | — | — | CN | disclosed |
| WO-2022232810-A1 | PURINE NUCLEOSIDES, THEIR INTERMEDIATES, AND METHODS OF PREPARATION THEREOF | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| US-11484545-B2 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2022-11-01 | — | — | US | disclosed |
| US-20220305044-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2022-09-29 | — | — | US | disclosed |
| CN-114903903-A | Compounds and methods for treating neurological and cardiovascular conditions | 阿斯特罗赛特制药公司 | 2022-08-16 | — | — | CN | disclosed |
| US-20220218712-A1 | TREATMENT OF ALZHEIMER'S DISEASE | SAINT LOUIS UNIVERSITY | 2022-07-14 | — | — | US | disclosed |
| US-20220117985-A1 | TREATMENT OF CHRONIC HEADACHES | UNIVERSITY OF MARYLAND, BALTIMORE | 2022-04-21 | — | — | US | disclosed |
| CN-109310695-B | Compounds and methods for treating neurological and cardiovascular conditions | 阿斯特罗赛特制药公司 | 2022-04-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12390483-B2 | Compounds and methods for treating neurological and cardiovascular conditions | TNNI3, CPT1B, TNNT2 | ADORA3 778/4885KCNH2 681/4885ABCG2 1912/4885 |
| US-20220218712-A1 | TREATMENT OF ALZHEIMER'S DISEASE | ADORA3, ADORA2A, ADORA1 | ADORA3 1/4885KCNH2 3479/4885ABCG2 516/4885 |
| US-20250345353-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | ADORA3 778/4885KCNH2 681/4885ABCG2 1912/4885 |
| US-11484545-B2 | Compounds and methods for treating neurological and cardiovascular conditions | TNNI3, CPT1B, TNNT2 | ADORA3 778/4885KCNH2 681/4885ABCG2 1912/4885 |
| US-20220305044-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | ADORA3 778/4885KCNH2 681/4885ABCG2 1912/4885 |
| US-20250177405-A1 | METHODS OF TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885KCNH2 1268/4885ABCG2 549/4885 |
| US-12239654-B2 | Compounds and methods for treating neurological and cardiovascular conditions | TNNI3, CPT1B, TNNT2 | ADORA3 778/4885KCNH2 681/4885ABCG2 1912/4885 |
| US-20220117985-A1 | TREATMENT OF CHRONIC HEADACHES | ADORA3, ADORA2B, ADORA2A | ADORA3 1/4885KCNH2 436/4885ABCG2 1223/4885 |
| US-12397010-B2 | Treatment of chronic headaches | ADORA3, ADORA2B, ADORA2A | ADORA3 1/4885KCNH2 436/4885ABCG2 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.